Northwest Biotherapeutics | NWBO - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Agenus USD 6.21M 4.34M 2026-03
AstraZeneca USD 4.07B 1.73B 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Celldex Therapeutics USD 14.84M 1.74M 2026-09
Eisai JPY 114.83B 4.71B 2026-06
Merck USD 2.86B 25M 2026-09
Northwest Biotherapeutics USD 6.54M 534K 2026-03
Pfizer USD 3.28B 132M 2026-09
Plus Therapeutics USD 4.26M 779K 2026-03
Roche Holding CHF 6.37B 908M 2026-06